| 1 |
Johnston A, Holt DW. Immunosuppressant drugs--the role of therapeutic drug monitoring[J]. Br J Clin Pharmacol, 2001,52(Suppl 1):61S-73S.
|
| 2 |
Zhang Y, Zhang R. Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs[J]. Drug Test Anal, 2017,10(1):81-94.
|
| 3 |
Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice[J].Clin Ther, 2002,24(3):330-350.
|
| 4 |
Keown P, Kahan BD, Johnston A, et al. Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997)[J]. Transplant Proc, 1998,30(5):1645-1649.
|
| 5 |
Srinivas NR. Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration data[J]. Biopharm Drug Dispos, 2015,36(9):575-586.
|
| 6 |
王磊，王红春，李培余，等. 两种检测骨髓移植患者环孢素A血药浓度方法的比较[J/CD].中华临床实验室管理电子杂志, 2017,5(4):241-245.
|
| 7 |
陈佩雷，邵传锋. FPIA和HPLC法在CSA血药浓度测定的比较分析[J]. 中外医疗, 2013,32(5):139.
|
| 8 |
宋晓勇，张永州，吴先闯，等. EMIT法与HPLC法测定人血浆中环孢素A浓度的比较研究[J]. 中国药房, 2011,22(26):2443-2445.
|
| 9 |
王磊，刘红星，孙文利. HPLC-MS/MS法在骨髓移植患者全血CSA及AM1浓度测定中的应用[J]. 重庆医学, 2017,46(23):3234-3237.
|
| 10 |
王磊，孙文利，李培余，等. 环孢素A血药浓度检测方法比较分析[J/CD]. 中华临床医师杂志(电子版), 2017,11(3):417-421.
|
| 11 |
王波，李鹏飞，马萍，等. LC-MS/MS和荧光偏振法监测环孢素A血药浓度的相关性研究[J]. 质谱学报, 2012,33(1):28-31.
|
| 12 |
谢服役，王峰，吴巧萍. CMIA、FPIA及MS在全血环孢霉素A浓度监测中的对比分析[J]. 医学研究杂志, 2012,41(4):118-120.
|
| 13 |
伍三兰，马林，陈东生，等. 酶扩大免疫测定技术与荧光偏振免疫法测定全血环孢素浓度的比较[J]. 中国医院药学杂志, 2012, 32(4):295-298.
|
| 14 |
郭玮，朱建锋，潘柏申. 克隆酶供体免疫测定法在环孢菌素A浓度监测中的应用[J]. 临床检验杂志, 2003,21(2):93-94.
|
| 15 |
李朋梅，刘晓，张镭，等. ARCHITECT与TDx测定环孢素A血药浓度相关性研究[J]. 中国药学杂志, 2011,46(13):1020-1022.
|
| 16 |
程丽静，赵冠人，冯端浩. CMIA法与FPIA法检测环孢素A血药浓度的比较研究[J]. 中国药房, 2013,24(42):3971-3973.
|
| 17 |
刘晓，张相林，张镭，等. 单克隆荧光偏振免疫法、多克隆荧光偏振免疫法和高效液相色谱法分别测定环孢素A血药浓度结果的相关性探讨[J]. 中国药学杂志, 2009,44(10):790-793.
|
| 18 |
Sun B, Guo Y, Gao J, et al. Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients[J]. Pharmacogenomics, 2017,18(16):1503-1513.
|
| 19 |
Crettol S, Venetz JP, Fontana M, et al. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients[J]. Ther Drug Monit, 2008,30(6):689-699.
|
| 20 |
Bouamar R, Hesselink DA, van Schaik RH, et al. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation[J]. Ther Drug Monit, 2011,33(2):178-184.
|
| 21 |
Zhu HJ, Yuan SH, Fang Y, et al. The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis[J]. Pharmacogenomics J, 2011,11(3):237-246.
|
| 22 |
Li DY, Teng RC, Zhu HJ, et al. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients[J]. Int J Clin Pharmacol Ther, 2013,51(6):466-474.
|
| 23 |
Moes DJ, Swen JJ, den Hartigh J, et al. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation[J]. CPT Pharmacometrics Syst Pharmacol, 2014,3:e100.
|
| 24 |
Tang HL, Ma LL, Xie HG, et al. Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis[J]. Pharmacogenet Genomics, 2010,20(9):525-531.
|
| 25 |
Santoro A, Felipe CR, Tedesco-Silva H, et al. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients[J]. Pharmacogenomics, 2011,12(9):1293-1303.
|
| 26 |
Sharaki O, Zeid M, Moez P, et al. Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients[J]. Mol Biol Rep, 2015,42(1):105-117.
|
| 27 |
Lee J, Wang R, Yang Y, et al. The efect of ABCB1 C3435T polymorphism on cyclosporine dose requirements in kidney transplant recipients: a meta-analysis[J]. Basic Clin Pharmacol Toxicol, 2015,117(2):117-125.
|
| 28 |
中华医学会儿科学分会临床药理学组. 儿童治疗性药物监测专家共识[J]. 中华儿科杂志, 2015,53(9):650-659.
|